EBV-negative aggressive B-cell lymphomas of donor origin after allogeneic hematopoietic stem cell transplantation: a report of three cases

Abstract Post-transplant lymphoproliferative disorders (PTLD) develop as a consequence of iatrogenic immunosuppression, and the majority is associated with EBV. PTLD after allogeneic hematopoietic stem cell transplantation (allo-HCT) are rare. Most cases are donor-derived, reflecting immune reconstitution by malignant transformed donor cells, and are EBV-positive. We report three unusual cases of aggressive EBV-negative PTLD of monomorphic type after allo-HCT. All cases were of donor origin and arose with long latency, 4–12 years after HCT. The patients had a history of severe graft-versus-host disease (GVHD) resulting in prolonged immunosuppression before the diagnosis of lymphoma. In one case, the temporal evolution of the malignant clone was analyzed by clone-specific PCR targeting the immunoglobulin heavy chain rearrangement. A tumor-specific product was already detected 3 years before lymphoma development. This indicates that chronic antigenic stimulation and reduced immune surveillance, may promote the outgrowth of premalignant donor-derived clones after acquisition of additional genetic alterations.

[1]  S. Swerdlow WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues , 2017 .

[2]  G. Verhoef,et al.  Clinicopathologic Comparison of Plasmablastic Lymphoma in HIV-positive, Immunocompetent, and Posttransplant Patients: Single-center Series of 25 Cases and Meta-analysis of 277 Reported Cases , 2014, The American journal of surgical pathology.

[3]  G. Enblad,et al.  A population-based study of 135 lymphomas after solid organ transplantation: The role of Epstein-Barr virus, hepatitis C and diffuse large B-cell lymphoma subtype in clinical presentation and survival , 2014, Acta oncologica.

[4]  J. Teruya-Feldstein,et al.  Posttransplant Lymphoproliferative Disorder Complicating Hematopoietic Stem Cell Transplantation in a Patient With Dyskeratosis Congenita , 2013, International journal of surgical pathology.

[5]  P. Van Loo,et al.  Gene Expression Profiling Reveals Clear Differences Between EBV‐Positive and EBV‐Negative Posttransplant Lymphoproliferative Disorders , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[6]  K. Elenitoba-Johnson,et al.  Aggressive genetic “double-hit” B-cell lymphoma following renal transplantation: case report , 2013, Journal of Hematopathology.

[7]  W. Sanger,et al.  Early onset, EBV(-) PTLD in pediatric liver-small bowel transplantation recipients: a spectrum of plasma cell neoplasms with favorable prognosis. , 2013, Blood.

[8]  W. Klapper,et al.  Plasmablastic Posttransplant Lymphoma: Cytogenetic Aberrations and Lack of Epstein-Barr Virus Association Linked With Poor Outcome in the Prospective German Posttransplant Lymphoproliferative Disorder Registry , 2012, Transplantation.

[9]  F. Fend,et al.  Plasmablastic lymphoma and related disorders. , 2011, American journal of clinical pathology.

[10]  K. Loeb,et al.  Donor cell-derived leukemia and myelodysplastic neoplasm: unique forms of leukemia. , 2011, American journal of clinical pathology.

[11]  R. Pfeiffer,et al.  Risk factors for early‐onset and late‐onset post‐transplant lymphoproliferative disorder in kidney recipients in the United States , 2011, American journal of hematology.

[12]  K. Blum,et al.  Mantle cell lymphoma 12 years after allogeneic bone marrow transplantation occurring simultaneously in recipient and donor. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  D. Schiff,et al.  Primary central nervous system post‐transplantation lymphoproliferative disorder , 2010, Cancer.

[14]  M. Kaminski,et al.  Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  E. Jaffe,et al.  Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. , 2009, Blood.

[16]  Lawrence R. Johnson,et al.  Impact of Epstein-Barr Virus in Monomorphic B-cell Posttransplant Lymphoproliferative Disorders: A Histogenetic Study , 2006, The American journal of surgical pathology.

[17]  H. Gabbert,et al.  A new method for optimizing multiplex DNA microsatellite analysis in low quality archival specimens. , 2005, Anticancer research.

[18]  E. Woodle,et al.  Posttransplant lymphoproliferative disorder: significance of central nervous system involvement. , 2005, Transplantation proceedings.

[19]  T. Larson,et al.  Differences between Early and Late Posttransplant Lymphoproliferative Disorders in Solid Organ Transplant Patients: Are They Two Different Diseases? , 2005, Transplantation.

[20]  D. Rizzieri,et al.  Posttransplant Lymphoproliferative Disorder Following Nonmyeloablative Allogeneic Stem Cell Transplantation , 2004, The American journal of surgical pathology.

[21]  M Hummel,et al.  Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936 , 2003, Leukemia.

[22]  B. Petit,et al.  Influence of host-recipient origin on clinical aspects of posttransplantation lymphoproliferative disorders in kidney transplantation. , 2002, Transplantation.

[23]  J. Tanner,et al.  The Epstein–Barr virus and post‐transplant lymphoproliferative disease: interplay of immunosuppression, EBV, and the immune system in disease pathogenesis , 2001, Transplant infectious disease : an official journal of the Transplantation Society.

[24]  R. Porcher,et al.  Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  T. Lipp,et al.  Treatment of Adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL). , 2000, Hematology/oncology clinics of North America.

[26]  S. Swerdlow,et al.  Epstein-Barr virus-negative post-transplant lymphoproliferative disorders: a distinct entity? , 2000, The American journal of surgical pathology.

[27]  D. Huhn,et al.  Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. , 1997, Blood.

[28]  F. Davi,et al.  Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity? , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  B. Leber,et al.  B‐cell lymphoma of recipient origin 9 years after allogeneic bone marrow transplantation for T‐cell acute lymphoblastic leukaemia , 1993, British journal of haematology.

[30]  A. Webster,et al.  Post-transplant lymphoproliferative disorders , 2016, Nature Reviews Disease Primers.

[31]  D. Neuberg,et al.  Molecular ontogeny of donor-derived follicular lymphomas occurring after hematopoietic cell transplantation. , 2012, Cancer discovery.

[32]  Yu-Hong Chen,et al.  Clinicopathologic spectrum and EBV status of post-transplant lymphoproliferative disorders after allogeneic hematopoietic stem cell transplantation , 2012, International Journal of Hematology.